Recombinant LIV-1 (Ladiratuzumab Biosimilar) 抗体
Quick Overview for Recombinant LIV-1 (Ladiratuzumab Biosimilar) 抗体 (ABIN7581553)
抗原
抗体类型
适用
宿主
克隆类型
标记
应用范围
-
-
Expression System
- CHO Cells
-
原理
- Anti-LIV-1 / SLC39A6 Reference Antibody (ladiratuzumab)
-
序列
- QVQLVQSGAE VKKPGASVKV SCKASGLTIE DYYMHWVRQA PGQGLEWMGW IDPENGDTEY GPKFQGRVTM TRDTSINTAY MELSRLRSDD TAVYYCAVHN AHYGTWFAYW GQGTLVTVSS ASTKGPSVFP LAPSSKSTSG GTAALGCLVK DYFPEPVTVS WNSGALTSGV HTFPAVLQSS GLYSLSSVVT VPSSSLGTQT YICNVNHKPS NTKVDKKVEP KSCDKTHTCP PCPAPELLGG PSVFLFPPKP KDTLMISRTP EVTCVVVDVS HEDPEVKFNW YVDGVEVHNA KTKPREEQYN STYRVVSVLT VLHQDWLNGK EYKCKVSNKA LPAPIEKTIS KAKGQPREPQ VYTLPPSRDE LTKNQVSLTC LVKGFYPSDI AVEWESNGQP ENNYKTTPPV LDSDGSFFLY SKLTVDKSRW QQGNVFSCSV MHEALHNHYT QKSLSLSPG,DVVMTQSPLS LPVTLGQPAS ISCRSSQSLL HSSGNTYLEW YQQRPGQSPR PLIYKISTRF SGVPDRFSGS GSGTDFTLKI SRVEAEDVGV YYCFQGSHVP YTFGGGTKVE IKRTVAAPSV FIFPPSDEQL KSGTASVVCL LNNFYPREAK VQWKVDNALQ SGNSQESVTE QDSKDSTYSL SSTLTLSKAD YEKHKVYACE VTHQGLSSPV TKSFNRGEC
-
产品特性
- Anti-LIV-1 / SLC39A6 Reference Antibody (ladiratuzumab) is expressed from CHO. The heavy chain type is huIgG1, and the light chain type is hukappa. It has a predicted MW of 145.5 kDa.
-
纯度
- >95 %
-
亚型
- IgG1
-
-
-
-
应用备注
- Optimal working dilution should be determined by the investigator.
-
说明
-
Therapeutic Agents by Target and Mechanism: LIV-1 inhibitors
-
限制
- 仅限研究用
-
-
-
状态
- Lyophilized
-
浓度
- 1 mg/mL
-
缓冲液
- 25 mM histidine, 8 % sucrose, 0.01 % Tween80 pH 6.2
-
储存条件
- 4 °C,-80 °C
-
储存方法
- +4°C,-80°C
-
-
- LIV-1 (Ladiratuzumab Biosimilar)
-
物质类
- Biosimilar
-
分子量
- 145.5 kDa
-
UniProt
- Q13433
抗原
-